Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science




Sarah Bolander, DMSc, MMS, PA-C, DFAAPA


Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease affecting up to 4.2% of people in the United States. CRSwNP results in a variety of symptoms that decrease health-related quality of life (HRQoL). The mainstay of treatment involves intranasal corticosteroids, sinonasal lavage with saline, and fiberoptic endoscopic sinus surgery (FESS). Despite treatment, almost a quarter of patients will suffer a relapse of polyp growth with a reduction of HRQoL within one year. Recently, biologic therapies have been introduced as a new treatment aimed at blocking various parts of the inflammatory pathway responsible for nasal polyp growth. Biologics are both safe and effective in improving HRQoL.


Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.